Novo Nordisk's Return-to-Office: A Competitive Strategy?

Novo Nordisk mandates a full return to the office for all employees while cutting 9,000 jobs to save $1.25 billion. Is this a strategic move to boost collaboration and beat competitors like Eli Lilly in the obesity treatment market, or a sign of a company under pressure? Find out how these drastic changes aim to reshape Novo Nordisk's future. Hosted on Acast. See acast.com/privacy for more information.